Characterisation and application of a bovine U6 promoter for expression of short hairpin RNAs
- 13k Downloads
The use of small interfering RNA (siRNA) molecules in animals to achieve double-stranded RNA-mediated interference (RNAi) has recently emerged as a powerful method of sequence-specific gene knockdown. As DNA-based expression of short hairpin RNA (shRNA) for RNAi may offer some advantages over chemical and in vitro synthesised siRNA, a number of vectors for expression of shRNA have been developed. These often feature polymerase III (pol. III) promoters of either mouse or human origin.
To develop a shRNA expression vector specifically for bovine RNAi applications, we identified and characterised a novel bovine U6 small nuclear RNA (snRNA) promoter from bovine sequence data. This promoter is the putative bovine homologue of the human U6-8 snRNA promoter, and features a number of functional sequence elements that are characteristic of these types of pol. III promoters. A PCR based cloning strategy was used to incorporate this promoter sequence into plasmid vectors along with shRNA sequences for RNAi. The promoter was then used to express shRNAs, which resulted in the efficient knockdown of an exogenous reporter gene and an endogenous bovine gene.
We have mined data from the bovine genome sequencing project to identify a functional bovine U6 promoter and used the promoter sequence to construct a shRNA expression vector. The use of this native bovine promoter in shRNA expression is an important component of our future development of RNAi therapeutic and transgenic applications in bovine species.
KeywordsEnhance Green Fluorescent Protein shRNA Expression Enhance Green Fluorescent Protein Expression MDBK Cell shRNA Expression Vector
RNA interference (RNAi), a method of sequence specific gene knockdown, has been used to analyse gene function in plants, invertebrates, and more recently mammalian cells [1, 2, 3]. The conserved RNAi pathway involves the processing of double stranded RNA (dsRNA) duplexes into 21–23 nucleotide (nt) molecules known as small interfering RNAs (siRNA) to initiate gene knockdown [4, 5, 6]. Since the discovery of RNAi in animals  the use of long dsRNA in lower eukaryotes, especially in the model organism Caenorhabditis elegans, has been used to determine gene function [8, 9]. However, in mammalian systems the cellular uptake of long dsRNA induces an antiviral defence mechanism initiated by interferon (IFN), leading to non-specific translational shutdown and apoptosis [10, 11, 12].
This non-specific cellular activity can be circumvented by the direct transfection of either chemically synthesised or in vitro transcribed siRNAs of approximately 21 nt in length into mammalian cells [1, 13]. These short molecules do not activate the IFN response, but can induce reliable and efficient transient knockdown of target genes [14, 15]. As a consequence, the development of DNA-based vectors for expression of short hairpin RNA (shRNA) molecules that are processed within the cell to produce active siRNA molecules has progressed rapidly [16, 17, 18]. Such DNA expression constructs have achieved highly efficient gene knockdown without induction of the IFN response.
DNA-based vectors offer some additional advantages over chemical and in vitro synthesised siRNA. Vector construction is much less expensive compared to the chemical synthesis of siRNA, selection of transfected cells is possible via antibiotic selection and the option of inducible shRNA transcription is also available. shRNA expression vectors have been engineered using both viral (including retroviral , adenoviral  and lentiviral  vectors), and plasmid systems [16, 17, 18]. These vectors often utilize promoters from a small class of pol. III promoters [22, 23] to drive the expression of shRNA. Promoters of this type are preferred because they naturally direct the synthesis of small, highly abundant non-coding RNA transcripts, with defined termination sequences consisting of 4–5 thymidines (Ts) and have no requirement for downstream promoter elements [22, 23, 24].
The human U6 snRNA promoter is the best studied type III pol. III promoter. It has characteristic promoter elements known as the enhancer and core regions [25, 26], and is frequently used in RNAi expression vectors. A total of nine full-length U6 loci have been identified from the human genome . These genes are dispersed throughout the genome and five of these are potentially active, including the previously described human U6 promoter, now denoted U6-1. In the current study we describe the characterisation of the bovine U6 snRNA promoter and its expression of shRNA molecules in bovine cells. We used a PCR based cloning strategy to construct a plasmid vector that features the bovine U6 promoter to drive expression of shRNA molecules directed at the exogenously expressed Enhanced Green Fluorescent Protein (EGFP) and the endogenous bovine gene, glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Results and discussion
Characterisation of a bovine U6 promoter
shRNA expression vector construction
In all constructs, the first nucleotide of the predicted shRNA was a guanine (G) residue, corresponding to the first nucleotide of the native U6 snRNA. An XbaI restriction enzyme site was engineered downstream of the termination signal to allow screening for full-length shRNA products inserted into pGEM-T Easy (Promega) which lacks an XbaI site. All final shRNA expression constructs consisted of either the full-length bovine or mouse U6 promoter, a shRNA sense sequence, a loop sequence, a shRNA antisense sequence, a termination sequence and an XbaI site.
Activity of the bovine U6 promoter measured by EGFP knockdown
To analyse the function of the bovine U6 promoter, the level of EGFP expression in cells cotransfected with pBovineU6-shEGFP and pEGFP-N1 (Clonetech) were directly compared with EGFP expression in cells cotransfected with pBovineU6-shScrambled and pEGFP-N1. An indication of the bovine promoter efficiency was provided by direct comparison to the level of EGFP knockdown by the same shRNA molecule expressed from pMouseU6-shEGFP. Prior to validation in bovine cells, both mouse and bovine U6 promoter driven shRNA expression vectors were first validated in Vero cells. As this cell line lacks the interferon α, β and ω genes [31, 32], a significant reduction in EGFP expression could be attributed to RNAi and not the result of non-specific inhibition of protein translation characteristic of the IFN response triggered by expressed exogenous dsRNA.
To ensure that the observed reduction in EGFP expression could be directly attributed to RNAi induced by expressed shRNA, the transcription of these molecules was detected in transfected cells. A radiolabelled RNA probe complementary in sequence to the EGFP shRNA sequence was used in an RNAse protection assay to visualise these molecules. The mouse microRNA (miRNA) miR-16 probe used as a loading control for each condition produced a strong signal at the expected size for all samples (Fig. 3C). The EGFP shRNA was detected only in those samples that were transfected with either of the EGFP shRNA vectors (Fig. 3C). There were no obvious differences in the amount of shRNA produced by either the mouse or bovine U6 promoters.
Activity of the bovine U6 promoter measured by GAPDH knockdown
We mined data from the bovine sequencing project and identified a bovine U6 snRNA promoter that is the putative bovine homologue of the human U6-8 snRNA promoter. This pol. III promoter sequence contains a number of functional sequence elements that are characteristic of this type of promoter and are essential for promoter function. The bovine U6 promoter sequence was used in the construction of plasmid based shRNA expression vectors pBovineU6-shEGFP and pBovineU6-shGapdh. These vectors efficiently induced RNAi in MDBK and Vero cells through production of shRNA molecules targeted at the exogenously expressed reporter gene EGFP, and the endogenous bovine gene GAPDH. The use of this promoter sequence and the shRNA vector cloning strategy described here will be advantageous in RNAi functional genomic experiments in bovine cells. The characterisation of this U6 promoter is an important step in the development of novel bovine species specific RNAi based therapeutics. For ethical reasons it is essential to minimise the introduction of non-bovine DNA sequences, consequently this research could be of significance in the transgenic delivery of shRNA molecules in bovine species.
Bovine U6 promoter isolation
Synthesized oligonucleotides used in this study
A region of the bovine genome homologous to a bovine BAC-end sequence (GenBank Accession no. CC528275) predicted to contain a U6 snRNA promoter was amplified from Bos taurus genomic DNA isolated from whole blood using Wizard Genomic DNA Purification kit (Promega). First round PCR amplification used forward primer LL16 with a reverse primer TD66 designed from the highly conserved human U6 snRNA sequence. This PCR product was then used as template for semi-nested PCR with LL16 and antisense primer TD72 located 11 nt upstream of TD66 in the U6 snRNA sequence. The second round PCR produced a clean band of expected size (507 nt) that was gel purified using QIAquick gel extraction kit (Qiagen), ligated into pGEM-T Easy (Promega) as per the manufacturers instructions and sequenced.
Expression vector construction and shRNA target sites
A bovine U6 EGFP shRNA construct (pBovineU6-shEGFP) was produced using a two-step PCR approach. The 1st PCR paired LL16 with reverse primer LL23, comprising the last 20 nt of the promoter sequence, EGFP shRNA sense, loop, and 3 nt EGFP shRNA antisense sequence. This PCR product was used as template for semi-nested PCR to produce the full-length shRNA template, using LL16 and reverse primer LL13 with a short overlapping region, comprising the 4nt EGFP shRNA sense, loop, EGFP shRNA antisense, termination and XbaI.
A mouse U6 EGFP shRNA construct (pMouseU6-shEGFP) was produced using one-step PCR with pSilencer 1.0-U6 siRNA Expression Vector (Ambion) as template. Universal primer M13 Forward was paired with reverse primer TD134, comprising the last 20 nt of the mouse promoter, and all other EGFP shRNA components.
The EGFP shRNA sequence used for both bovine and mouse vectors, had been shown previously to be effective in silencing gene expression . A bovine U6 EGFP scrambled shRNA sequence (pBovineU6-shScrambled) was produced using a sequence that showed no significant homology to available monkey or bovine sequence data. Forward primer LL16 was paired with reverse primer LL31 comprising the last 20 nt of the bovine U6 promoter, and all other EGFP scrambled shRNA components.
Three siRNAs were designed based on the bovine GAPDH sequence obtained from GeneBank (Accession no. U85042) using the criteria described by Elbashir et al., 2002 (37). Target sites for bovine GAPDH were; GAPDH #1 (5'-AAGTTCAACGGCACAGTCAAG-3'); GAPDH #2 (5'-AACTTGACTGTGCCGTTGAAC-3'); GAPDH #3 (5'-AAGGTCATCCATGACCACTTT-3'). To generate siRNAs, oligonucleotides for sense and antisense-strands of each siRNA together with T7 promoter sites were synthesized and siRNAs were produced using the Ambion Silencer siRNA construction kit (Ambion). Oligonucleotides used for each were; GAPDH #1: LBG-as1 and LBG-as2; GAPDH #2: LBG-as3 and LBG-s4; GAPDH #3: LBG-as5 and LBG-s6 (Table 1).
A bovine U6 GAPDH shRNA expression construct (pBovineU6-shGapdh) was generated using a one-step PCR approach. LL16 was paired with LL05 which comprised the last 20 nt of the bovine U6 promoter and all other GAPDH shRNA sequence components including the GAPDH #1 siRNA sequence. Similarly, a mouse U6 GAPDH shRNA expression construct (pMouseU6-shGapdh) was also generated. M13 universal primer was paired with LL06, which also comprised the last 20 nt of the mouse U6 promoter and all other GAPDH shRNA components. All PCR products for shRNA expression constructs were ligated into pGEM-T Easy (Promega) and sequenced.
Cell culture and transfection
MDBK (Madin Darby Bovine Kidney) and Vero (African Green monkey kidney) cell lines were cultured in Eagle's minimal essential medium (EMEM) medium containing 10% fetal calf serum (FCS), 2 mM glutamine, 10 mM HEPES, supplemented with penicillin (100 U/ml) and streptomycin (100 μg/ml). All cells were cultured in humidified atmosphere containing 5% CO2 at 37°C. Vero cells were grown to approximately 80% confluence on either 24-well plates (Nunc) for Flow Cytometry, on 8-well chamber slides (Lab-Tek) for fluorescence microscopy, or 6-well plates for shRNA detection. Cotransfection with 500 ng for 24-well plates and chamber slides, or 2.5 μg for 6-well plates of plasmid DNA (shRNA plasmids and/or pEGFP-N1 (Clonetech)) was carried out using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. MDBK cells were grown to 80–90% confluence in 75 cm2 flasks (Corning), harvested and divided into aliquots of 1 × 106 cells per transfection. Approximately 2.5 μg of each plasmid was transfected per aliquot by electroporation using a Nucleofector (Amaxa) according to the manufacturer's instructions. Electroporated cells were dispensed into 8-well chamber slides for fluorescence microscopy, 6-well plates (Nunc) for flow cytometry or 24-well plates for Real-time PCR. Transfection of GAPDH siRNAs in MDBK cells grown to approximately 80% confluence on 24-well plates (Nunc) was achieved using Lipofectamine 2000 with approximately 10 nM of each siRNA.
EGFP and GAPDH knockdown assays
EGFP expression was monitored at 72-hour post-transfection using fluorescence microscopy (Leica DMLB). Vero and MDBK cells cultured in 8-well chamber slides were washed with PBSA and mounting solution was applied (9:1 glycerol: PBSA). Cells to be analysed by flow cytometry were trypsinized and washed in PBSA. Cells were then resuspended in 200 μL 0.01% sodium azide and 2% FCS in PBSA and analysed using a FACScalibur (Becton Dickinson) flow cytometer. Data analysis was performed using CELLQuest software (Becton Dickinson).
Real-time RT-PCR reactions were carried out 48-hours post-transfection. MDBK cells transfected with GAPDH siRNAs and GAPDH shRNA vectors were harvest and cDNA was produced using the Cells-to-cDNA II kit (Ambion) using random hexamers. cDNA (2.5 μL) was added to a 22.5 μL Real-time RT -PCR master mix containing 12.5 μL 2X TaqMan Universal PCR Master Mix (Applied Biosystems), 2.5 μL (9 μM) each of sense primer BovineGpdhF and antisense primer bovineGpdhR, 2.5 μL (2.5 μM) of TaqMan MGB Probe (bovineGpdhPROBE) (Applied Biosystems) and 2.5 μL RNase-free water (Table 1). For RNA normalization, an 18s rRNA PCR was performed for each cDNA using the same PCR reagents except for the primers and probes which were the Eukaryotic 18srRNA Endogenous Control (Applied Biosystems). Real-time PCR was carried out in a 7700 Sequence Detection Instrument (Applied Biosystems) using the following thermal cycling profile: 95°C 1 min, followed by 35 cycles of amplification (95°C 15s, 61°C 30s, 68°C 30s).
Detection of EGFP shRNAs was carried by out using an RNAse protection assay on extracts enriched for small RNAs isolated from transfected Vero cells using a mirVana miRNA Isolation Kit (Ambion). The RNA oligonucleotide LL91 was end labelled with [gamma-32P] ATP using a mirVana Probe & Marker Kit (Ambion) and hybridised to the enriched RNAs using the mirVana miRNA Detection Kit (Ambion). The RNA fragments were then separated by electrophoresis on a 15% denaturing polyacrylamide/ 8 M Urea gel and detected by autoradiography.
We thank Dr. Jef Hammond and Dr. Sandra Sapats for critically reading the manuscript. The technical assistance provided by Scott Tyack, Terry Wise, Matthew Bruce, Daniel Layton and Tony Pye was also greatly appreciated.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.